Virtus ETF Advisers’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
Other funds holding MYGN
Virtus ETF Advisers's MYGN Position: Q3 2026 in Review
Virtus ETF Advisers sold out of Myriad Genetics (MYGN) in Q3 2026, closing a stake of 20,502 shares — an estimated $117K sold.
Virtus ETF Advisers first reported a position in MYGN in Q4 2025 and held it in 3 quarters. The position peaked at $123K in Q4 2025. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.
- Virtus ETF Advisers reported no remaining Myriad Genetics position as of Q3 2026 after selling out during the quarter.
- Virtus ETF Advisers sold 20,502 Myriad Genetics shares in Q3 2026, an estimated $117K.
- Virtus ETF Advisers first reported a position in Myriad Genetics in Q4 2025 and held it in 3 quarters.
- Virtus ETF Advisers's Myriad Genetics position peaked at $123K in Q4 2025.
- 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.
Based on Virtus ETF Advisers's 13F filing for Q3 2026, filed 9 Nov 2026.